Two Sigma Advisers
CSTL icon

Two Sigma Advisers’s Castle Biosciences CSTL Stock Holding History

Two Sigma Advisers’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,899
Closed -$1.16M – 525
2025
Q4 		$1.16M Buy
29,899
+19,999
+202% +$645K ﹤0.01% 1424
2025
Q3 		$225K Sell
9,900
-2,100
-18% -$42.7K ﹤0.01% 2089
2025
Q2 		$245K Sell
12,000
-57,200
-83% -$1.06M ﹤0.01% 2040
2025
Q1 		$1.39M Buy
69,200
+57,700
+502% +$1.43M ﹤0.01% 1306
2024
Q4 		$306K Buy
+11,500
New +$350K ﹤0.01% 1971
2024
Q2 		– Sell
-19,000
Closed -$421K – 2485
2024
Q1 		$421K Sell
19,000
-13,100
-41% -$285K ﹤0.01% 1944
2023
Q4 		$693K Sell
32,100
-24,400
-43% -$429K ﹤0.01% 1789
2023
Q3 		$954K Sell
56,500
-36,500
-39% -$638K ﹤0.01% 1540
2023
Q2 		$1.28M Sell
93,000
-19,300
-17% -$391K ﹤0.01% 1432
2023
Q1 		$2.55M Sell
112,300
-19,800
-15% -$484K 0.01% 1153
2022
Q4 		$3.11M Sell
132,100
-21,300
-14% -$494K 0.01% 996
2022
Q3 		$4M Sell
153,400
-1,900
-1% -$53.3K 0.01% 849
2022
Q2 		$3.41M Buy
155,300
+131,500
+553% +$3.06M 0.01% 938
2022
Q1 		$1.07M Sell
23,800
-87,700
-79% -$3.62M ﹤0.01% 1599
2021
Q4 		$4.78M Buy
111,500
+31,700
+40% +$1.66M 0.01% 789
2021
Q3 		$5.31M Buy
79,800
+29,000
+57% +$2.04M 0.01% 758
2021
Q2 		$3.73M Sell
50,800
-11,300
-18% -$746K 0.01% 999
2021
Q1 		$4.25M Buy
62,100
+37,000
+147% +$2.78M 0.01% 918
2020
Q4 		$1.69M Buy
25,100
+13,300
+113% +$721K ﹤0.01% 1341
2020
Q3 		$607K Sell
11,800
-2,500
-17% -$111K ﹤0.01% 1733
2020
Q2 		$539K Buy
14,300
+800
+6% +$27.3K ﹤0.01% 1858
2020
Q1 		$402K Sell
13,500
-900
-6% -$27.2K ﹤0.01% 1889
2019
Q4 		$495K Sell
14,400
-2,000
-12% -$48.9K ﹤0.01% 1880
2019
Q3 		$297K Buy
+16,400
New +$364K ﹤0.01% 1925

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's CSTL Position: Q1 2026 in Review

Two Sigma Advisers sold out of Castle Biosciences (CSTL) in Q1 2026, closing a stake of 29,899 shares — an estimated $1.16M sold.

Two Sigma Advisers first reported a position in CSTL in Q3 2019 and held it in 24 quarters. The position peaked at $5.31M in Q3 2021. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Two Sigma Advisers reported no remaining Castle Biosciences position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 29,899 Castle Biosciences shares in Q1 2026, an estimated $1.16M.
  • Two Sigma Advisers first reported a position in Castle Biosciences in Q3 2019 and held it in 24 quarters.
  • Two Sigma Advisers's Castle Biosciences position peaked at $5.31M in Q3 2021.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.